Publication | Closed Access

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial

Hematological MalignancyMedicineChronic Myeloid LeukaemiaMixed-phenotype Acute LeukemiaHematologyClinical TrialsPharmacologyComplete Treatment DiscontinuationMyeloid NeoplasiaPharmacotherapyOncologyHealth Sciences